Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.

Pharmaceutics · 2021 · PMC8234109 · PMID 34205484

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The primary endpoint of OS did not reach statistical significance, although in the group treated with pemetrexed and bevacizumab in maintenance therapy, an increased PFS was reported.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.